AIM: TO STUDY EYES WITH EXTRAOCULAR DISSEMINATION (EORB), WITH THE FOLLOWING AIMS: first to establish the mean lag period and to understand various reasons for delayed presentation, second to study their imaging profiles and third to analyze histopathological features of eyes enucleated after neoadjuvant chemotherapy. METHODS: Prospective study of clinical and imaging features of EORBs (stage III and IV International Retinoblastoma Staging System) presenting to a tertiary eye care centre. Histopathological features of eyes enucleated after receiving neoadjuvant chemotherapy were analyzed. A pictorial illustration of the varied imaging profile of EORB was also presented. RESULTS: Over a period of one year, 97 eyes were diagnosed with retinoblastoma; 32 children (36 eyes) (37.1%) had EORB. Mean age 3.6±1.9 years, 71.9% males, 71.9% unilateral, 3.1% with positive family history and 40.6% with metastasis. On imaging, there was extrascleral involvement in 22.2%, involvement of orbital part of optic nerve in 33.3%, involvement of central nervous system in 27.8% and orbital wall involvement in 2.9% eyes. On histopathological analysis of eyes enucleated after neoadjuvant chemotherapy, 25.0% had no residual viable tumour tissue and rest all tumours were poorly differentiated. CONCLUSION: There are very few human malignancies where definitive treatment is started without any confirmed histopathological diagnosis and imaging plays an important role in diagnosis and appropriate staging of the disease. Chemotherapy has a variable effect on EORB, 75.0% of eyes with EORB had residual viable tumour tissue when enucleated after receiving neoadjuvant chemotherapy.
AIM: TO STUDY EYES WITH EXTRAOCULAR DISSEMINATION (EORB), WITH THE FOLLOWING AIMS: first to establish the mean lag period and to understand various reasons for delayed presentation, second to study their imaging profiles and third to analyze histopathological features of eyes enucleated after neoadjuvant chemotherapy. METHODS: Prospective study of clinical and imaging features of EORBs (stage III and IV International Retinoblastoma Staging System) presenting to a tertiary eye care centre. Histopathological features of eyes enucleated after receiving neoadjuvant chemotherapy were analyzed. A pictorial illustration of the varied imaging profile of EORB was also presented. RESULTS: Over a period of one year, 97 eyes were diagnosed with retinoblastoma; 32 children (36 eyes) (37.1%) had EORB. Mean age 3.6±1.9 years, 71.9% males, 71.9% unilateral, 3.1% with positive family history and 40.6% with metastasis. On imaging, there was extrascleral involvement in 22.2%, involvement of orbital part of optic nerve in 33.3%, involvement of central nervous system in 27.8% and orbital wall involvement in 2.9% eyes. On histopathological analysis of eyes enucleated after neoadjuvant chemotherapy, 25.0% had no residual viable tumour tissue and rest all tumours were poorly differentiated. CONCLUSION: There are very few humanmalignancies where definitive treatment is started without any confirmed histopathological diagnosis and imaging plays an important role in diagnosis and appropriate staging of the disease. Chemotherapy has a variable effect on EORB, 75.0% of eyes with EORB had residual viable tumour tissue when enucleated after receiving neoadjuvant chemotherapy.
Authors: Guillermo L Chantada; Ibrahim Qaddoumi; Serife Canturk; Vikas Khetan; Zhigui Ma; Kahaki Kimani; Baris Yeniad; Iyad Sultan; Rita S Sitorus; Nurdan Tacyildiz; David H Abramson Journal: Pediatr Blood Cancer Date: 2010-11-11 Impact factor: 3.167
Authors: S Canturk; I Qaddoumi; V Khetan; Z Ma; A Furmanchuk; C B G Antoneli; I Sultan; R Kebudi; T Sharma; C Rodriguez-Galindo; D H Abramson; G L Chantada Journal: Br J Ophthalmol Date: 2010-08-23 Impact factor: 4.638
Authors: Christopher Leander; Ligia C Fu; Armando Peña; Scott C Howard; Carlos Rodriguez-Galindo; Judith A Wilimas; Raul C Ribeiro; Barrett Haik Journal: Pediatr Blood Cancer Date: 2007-11 Impact factor: 3.167
Authors: A O Schueler; N Hosten; N E Bechrakis; A J Lemke; P Foerster; R Felix; M H Foerster; N Bornfeld Journal: Br J Ophthalmol Date: 2003-03 Impact factor: 4.638
Authors: Bina S Menon; Joseph Alagaratnam; Eni Juraida; Mahfuzah Mohamed; Hishamshah Ibrahim; Nyi Nyi Naing Journal: Pediatr Blood Cancer Date: 2009-02 Impact factor: 3.167